Anemia en Pacientes con Cirrosis

Causas y Mecanismos

• La cirrosis produce anemia de manera frecuente y a través de múltiples mecanismos fisiopatológicos, siendo más prevalente conforme avanza la severidad de la enfermedad hepática 1, 2, 3
• El sangrado por hipertensión portal, várices esofágicas, gastropatía portal hipertensiva, y otras complicaciones hemorrágicas contribuyen a la anemia 1, 3
• La deficiencia de hierro secundaria es resultado de sangrado oculto o evidente 1
• El mecanismo de eriptosis, inducido por bilirrubina y ácidos biliares elevados, causa muerte prematura de eritrocitos 2, 4
• La pérdida aumentada de eritrocitos genera más bilirrubina, que a su vez induce más eriptosis 2, 4
• Los pacientes con hiperbilirrubinemia presentan conteos eritrocitarios significativamente menores y conteos de reticulocitos significativamente mayores 2, 4
• El hígado es el sitio primario de eliminación de eritrocitos dañados en condiciones patológicas, mediante células de Kupffer que fagocitan eritrocitos eriptóticos 2, 4

Deficiencias Nutricionales

• La deficiencia de ácido fólico o vitamina B12 contribuye a la anemia en cirrosis 3
• La deficiencia de hierro, vitamina B6 debe optimizarse especialmente antes de procedimientos invasivos 3, 5

Supresión de Médula Ósea

• La supresión por enfermedad subyacente, como alcohol, hepatitis viral B o C, afecta la producción de eritrocitos 6, 7
• La reducción de trombopoyetina afecta la producción de megacariocitos y plaquetas 8

Hiperesplenismo y Secuestro

• La trombocitopenia asociada con hiperesplenismo se presenta en 80% de pacientes con cirrosis 6, 7

Manejo Recomendado

• Optimizar niveles de hemoglobina tratando deficiencias de hierro, ácido fólico, vitamina B6 y vitamina B12, especialmente antes de procedimientos invasivos 3, 5
• La suplementación de hierro es predictor significativo de aumento de hemoglobina 3
• La estrategia restrictiva de transfusión, transfundir cuando hemoglobina cae por debajo de 7 g/dL, con objetivo de 7-9 g/dL 3, 5
• No se recomienda la transfusión profiláctica de eritrocitos para disminuir riesgo de sangrado relacionado con procedimientos 3, 5

Anemia in Cirrhosis: Pathophysiological Mechanisms and Clinical Implications

Pathophysiological Mechanisms

• Portal hypertension causes splenic sequestration of red blood cells, with 78% of patients with clinically significant portal hypertension developing cytopenias, according to the Journal of Hepatology 9
• Folate, vitamin B12, vitamin B6, and iron deficiencies are common contributors to anemia in cirrhosis, particularly in patients with alcohol abuse, as reported by the Journal of Hepatology and Clinical and Molecular Hepatology 10, 11

Clinical Considerations

• Hematological adverse events, such as anemia, neutropenia, and thrombocytopenia, are particularly frequent in cirrhotic patients receiving interferon-based hepatitis C treatment due to portal hypertension and hypersplenism, as noted by the Journal of Hepatology and Clinical and Molecular Hepatology 10, 11
• Alcohol causes direct myeloid toxicity and contributes to nutritional deficiencies, making anemia particularly common and multifactorial in patients with alcohol-related cirrhosis, according to the Journal of Hepatology 9
• Growth factors, such as erythropoietin, may be helpful in controlling hematological side effects in cirrhotic patients receiving antiviral therapy, as reported by the Journal of Hepatology and Clinical and Molecular Hepatology 10, 11
• In liver transplant recipients with recurrent hepatitis C, 70% develop hemoglobin <10 g/dL during treatment, compared to 30% in non-transplanted patients, as noted by the Journal of Hepatology 12

Portal Hypertension‑Related Bleeding in Cirrhosis

Portal Hypertensive Gastropathy

• Portal hypertensive gastropathy is the most frequent bleeding source in cirrhosis, identified in ≈ 2 %–12 % of acute gastrointestinal bleeding episodes and responsible for chronic occult bleeding that leads to anemia in the majority of affected patients. 13

Portal Hypertensive Enteropathy and Colopathy

• Portal hypertensive enteropathy (small‑bowel) and portal hypertensive colopathy (colon) produce chronic gastrointestinal blood loss and anemia; they may occasionally present with acute bleeding. 14

Variceal Bleeding

• Acute hemorrhage from esophageal or gastric varices is a major cause of sudden blood loss‑related anemia in cirrhotic patients. 13

Gastric Antral Vascular Ectasia (GAVE)

• GAVE, although not directly linked to portal hypertension, is common in cirrhosis and contributes to bleeding‑related anemia. 13

Nutritional Deficiencies Contributing to Anemia

• Folate (vitamin B9) deficiency is especially prevalent in alcohol‑related cirrhosis due to inadequate dietary intake and the direct effects of alcohol on folate metabolism, leading to anemia. 15

• Vitamin B12 deficiency is a recognized cause of macrocytic anemia in patients with chronic liver disease. 15

Clinical Evaluation Algorithm for Anemia in Cirrhosis

• Systematic assessment should begin with a detailed bleeding history (e.g., melena, hematemesis, hematochezia, or occult gastrointestinal loss) to identify portal‑hypertension‑related sources. 13

• Evaluation of nutritional status—including dietary review and measurement of iron studies, folate, vitamin B12, and vitamin B6—is essential for detecting deficiency‑related anemia. 14

Epidemiology of Anemia Across Cirrhosis Stages

• The prevalence of anemia rises markedly with disease severity, affecting roughly 21 % of patients with compensated cirrhosis but up to 70 % of all individuals with cirrhosis. 15

All bullet points are supported by the cited references and reflect the current understanding of anemia mechanisms and evaluation in cirrhotic patients.